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Abstract
Radiation therapy remains as one of the main cancer treatment modalities. Typical regimens
for radiotherapy comprise a constant dose administered on weekdays, and no radiation on
weekends. In this paper, we examine adaptive dosages of radiation treatment strategies for
heterogeneous tumors using a dynamical system model that consist of radiation-resistant and
parental populations with unique interactive properties, namely, PC3 and DU145 prostate
cancer cell lines. We show that stronger doses of radiation given in longer time intervals, while
keeping the overall dosage the same, are effective in PC3 cell lines, but not in DU145 cell lines.
In addition, we tested an adaptive dosing schedule by administering a stronger dosage on
Friday to compensate for the treatment-off period during the weekend, which was effective in
decreasing the final tumor volume of both cell lines. This result creates interesting possibilities
for new radiotherapy strategies at clinics that cannot provide treatment on weekends.
Keywords: mathematical oncology, tumor growth, radiotherapy, dose fractionation, lotkavolterra model



1

Introduction

Radiotherapy is one of the predominant cancer treatment
modalities. Approximately 50% of all cancer patients receive radiotherapy treatments during the course of their
illness [11, 3], and it is estimated that radiation therapy contributes around 40% towards curative treatment
[2]. It is also a highly cost effective single modality treatment, accounting for only about 5% of the total cost of
cancer care [28]. Furthermore, advances in imaging techniques, computerized treatment planning systems, radiation treatment machines with improved X-ray production
and treatment delivery, as well as improved understanding of the radiobiology are all increasing the impact and
importance of radiotherapy [4].
In clinics, the dosing schedule of radiotherapy is standardized using daily doses of 1.8 to 2.0 for 39–45 fractions
[33]. This is called fractionation, where the total dosage is
divided into smaller doses that are given over a period of
one to two months. The specific dose for each patient depends on the location and severity of the tumor, as well as
the radiation-induced toxicity of normal tissues surrounding the tumor. Various studies focus on dose alteration to
improve radiotherapy outcome, including hypofractionation and hyperfractionation [26]. Hypofractionation is
a treatment regimen that uses higher doses of radiation
in fewer visits to lower the effects of accelerated tumor
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growth that typically occurs during the later stages of radiotherapy. On the other hand, hyperfractionation is a
strategy dividing the same total dose into more frequent
deliveries, for instance, radiation doses given more than
once a day. A recent study in [37] shows that increasing
the total dosage to 80 Gy, that corresponds to a biologically equivalent dose of 200 Gy for prostate cancer is
associated with improved outcome, but doses above that
level did not result in additional clinical benefit. Moreover, population-based research revealed an association
between overall survival of prostate cancer patients in
doses over 75.6 Gy [33]. However, the dosage schemes
that can be tested in clinical trials are very limited. Simulation using in-silico models can help address this limitation to test various dosing schedules without the concern
of toxicity to patients.
A large number of mathematical and computational
models have been developed to study tumor growth and
cancer treatments, including differential equations [24, 19,
8], multiphase models based on mixture theory [6, 31] or
phase field theory [30], and multiscale models that couple subcellular, cellular, and tissue scale phenomena [18].
The availability of detailed information about tumors has
undoubtedly stimulated this field to more complex models, although as the model complexity increases, it becomes more challenging to uniquely identify the model
parameter values [7]. In particular, often in the clinical
setting, it is not possible to collect appropriate amounts of
patients’ data to calibrate complex models. Hence, simple
2022 Volume 8(1) page 16
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models such as ordinary differential equations (ODEs) are
commonly used when dealing with clinical data. See [12,
9, 36] for recent literature using ODE models to calibrate
data of radiotherapy treated tumors as in our study.
Radiotherapy also has a long history of mathematical
modeling. Radiation dosing is typically modeled using
the linear-quadratic (L-Q) model [32, 13]. Several recent
studies have applied the L-Q model to patient-specific
data, in an effort to evaluate and predict individual responses to radiotherapy [29, 10, 31, 12]. Logistic type
of radiotherapy response has been proposed with a concept of proliferation saturation index, defined as the ratio
of tumor volume to the host-influenced tumor carrying
capacity, that correlates inversely with radiotherapy response [27, 25]. Other radiotherapy models, including
those assuming a dynamic carrying capacity, have been
developed to more accurately calibrate and predict individual patient response to radiotherapy [36].
Here, we investigate the effect of different radiotherapy regimens on the growth of two types of heterogeneous prostate tumors comprising radiation-sensitive (or
parental) populations and resistant populations that interact with one another. Although adaptive radiotherapy
and its potential clinical benefits have been proposed in
the clinical community since 1997 [35], it has not been
a common practice in the clinics until now [5]. However, recent improvements in imaging technologies along
with mathematical modeling have been proclaimed to allow us new opportunities toward patient-specific adaptive
radiation therapy [12]. Our work is in accordance with
this idea of using mathematical models to guide radiation
dose planning, which has been done for various types of
tumors, such as glioblastomas [22] and lung cancer [17].
The contribution of our study is to test the potential of
adaptive radiotherapy in silico for two types of prostate
cancer studied in [18]. The paper is structured as follows. Section 2 summarizes the mathematical model that
is used to describe the growth of heterogeneous cancer
and its response to radiotherapy with biological interpretations of the model parameters. We also describe how
radiotherapy fractionation treatments are incorporated
into the model in order to properly simulate cell death
due to radiotherapy. In Section 3 we explore two different scenarios on dose fractionation. Section 3.1 studies a
constant dosage treatment, while we change the dosage
and time interval between the administration of radiation. The overall dosage is kept constant. In section 3.2,
we study a strategy to overcome the clinical radiotherapy
schedule with no radiotherapy treatments being administered on weekends. We compare the strategy of changing
the dosage to be more heavily concentrated on Fridays at
the end of the week to a dosage that is spread out evenly.
Section 4 concludes our paper and summarizes our key
results. In addition, it includes our proposed fractionawww.sporajournal.org
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tion scheme that incorporates our findings into a possible
dosage plan.

2

Mathematical Model of Cancer
Growth and Radiotherapy

The Lotka-Volterra model is one of the typical approaches
to describe the interactions between multiple types of cancer cells [15, 38, 14, 23, 18, 20]. We also employ the LotkaVolterra model to describe the growth of mixtures consisting of parental and radioresistant tumor cell populations.
The equation tracks the dynamics of Vc (t), which is the
volume of the parental tumor population, or the “control”, in other words, the radiation-sensitive population,
and Vr (t), which is the volume of the radiation-resistant
tumor population.


Vc
Vr
dVc
= pc Vc 1 −
− λr
,
dt
Kc
Kc


(1)
dVr
Vr
Vc
= pr Vr 1 −
− λc
.
dt
Kr
Kr
The parameters used in the Lotka-Volterra model each
have their own biological function. The rate of growth
of the control population is pc , and the rate of growth
of the radio-resistant population is pr . Kc is the carrying capacity of the control population, the maximum
volume to which the radio-sensitive or parental population is limited to, and Kr is the carrying capacity of the
radioresistant population. In addition, λc and λr model
the interaction between the two populations, where λc describes the effect that the parental cell population has on
radioresistant cells, and λr describes the effect that the
radioresistant cell population has on the parental cells.
We note that −1 ≤ λc , λr ≤ 1. The signs of the interaction parameters λc and λr need not be equivalent. A
positive λc parameter represents a detrimental effect on
Vr , or the volume of the resistant tumor population, and
a negative λc parameter represents a beneficial effect on
Vr . The same is true for the effects of λr on Vc . If both
interaction parameters are positive then this represents
a competitive interaction between the two tumor populations, and if both are negative then this represents a
mutualistic interaction. One positive and one negative
interaction parameters signify that one tumor population
exerts a positive effect on the other while the latter exerts
a negative effect on the former tumor population, a socalled antagonistic interaction. An interaction parameter
of 0 represents no effect on the other tumor population.
All model parameters and their biological interpretations
are summarized in Table 1.
We now explain how we incorporate treatment with
radiotherapy in the cancer model Eq. (1). We consider
2022 Volume 8(1) page 17
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Table 1: Model parameters and their biological interpretation.
Parameter
Vc (t)
Vr (t)
pc
pr
Kc
Kr
λc
λr

Biological meaning
Volume of the control (radiation-sensitive/parental) tumor population at time t
Volume of the radiation-resistant tumor population at time t
Rate of growth of the control population
Rate of growth of the radio-resistant population
Carrying capacity of the control population
Carrying capacity of the radio-resistant population
Effect of the control cell population on the radio-resistant cells
Effect of the radio-resistant cell population on the control cells

αc , βc
αr , βr

Radio-sensitivity parameter of control cells
Radio-sensitivity parameter of radio-resistant cells

Table 2: A summary of the parameter values used in the simulation for prostate cancer cell lines, PC3 and DU145.
The pre-treatment parameters p, K, and λ are taken from [18], provided in supplementary Table S1 and Figure 2d
of [18]. The radiotherapy parameters α and β are estimated from data in supplementary Figure S1b in [18].
Cell line
PC3
DU145

Units

pc
pr
Kc
Kr

0.36
0.48
0.85
2.0

0.6
0.36
0.75
1.4

day−1
day−1
mm3
mm3

λc
λr

0.2
0.0

0.25
−0.5

day−1 mm−3
day−1 mm−3

αc
αr
βc
βr

0.43
0.3
0.0407
0.0402

0.2843
0.23
0.0161
0.0124

Gy−1
Gy−1
Gy−2
Gy−2

Parameter

a typical tumor treatment regimen in which daily doses
of d Gy are administered Monday through Friday for 6
weeks. We use the linear-quadratic model [16] to account
for the effect of radiotherapy. This model assumes that
the fraction of cells that survive exposure to a dose d of
radiotherapy is given by
2

Survival fraction = e−αd−βd ,

(2)

where α and β are tissue specific radiosensitivity parameters that model single and double strand breaks of the
DNA [21]. We assume that the effect of radiotherapy is
instantaneous, with the non-surviving cell fraction immediately removed when therapy is administered. In particular, we denote the dosing schedule by u(t) as the following summation of indicator functions,
u(t) =

N
X
i=1

www.sporajournal.org

δ(t − ti ),

where δ(t) is a Dirac-delta function that is δ(0) = 1 and
zero elsewhere. This makes u(t) to be one only at ti
(for i = 1, 2, . . . , N ), the times at which radiotherapy is
delivered. As we combine the radiotherapy model with
the radiosensitivity cancer growth model, we have


dVc
Vc
Vr
= pc Vc 1 −
− λr
,
dt
Kc
Kc
2

− (1 − e−αc d−βc d ) u(t)Vc ,


dVr
Vr
Vc
= pr Vr 1 −
− λc
dt
Kr
Kr
2

− (1 − e−αr d−βr d ) u(t)Vr .
|
{z
}
cell death due to RT

(4)

(5)

(3) Here, αc and βc are radiosensitivity parameters for the
control cells, and αr and βr are for the resistant cells.
2022 Volume 8(1) page 18
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3

Simulation of Radiotherapy
Dosage Fractionation

These simulations will investigate dosage strategies in two
separate prostate cancer cell lines, PC3 and DU145. Important to note when discussing each cell lines’ response
to varying dosage strategies is that each cell line varies in
their growth rate, response to radiation, carrying capacity, and in the interaction parameters between control and
radio-resistant cell populations. For instance, regarding
the interaction between the control and radio-resistant
population, PC3 has competitive interaction, while the
control population of DU145 has antagonistic relation to
the radio-resistant population and only the control population benefits from coexistence. Also, regarding sensitivity to radiotherapy, PC3 is more sensitive to the treatment compared to DU145. See Table 2 for the parameter
values.
In our simulations, we consider a period of 6 weeks
of radiotherapy treatment with an initial 2 week cancer growth period. The dosage plans that we study are
described in each section in detail, but see Figure 1 for
some examples and a brief summary. The initial condition for the model is taken as Vc (0) = 0.5mm3 , and
Vr (0) = 0.5mm3 , assuming the parental and resistant tumor cell lines initially in a 1:1 ratio consistent with conventional experimental methods [18]. Although we test
only for 1:1 ratio, we report on the control and resistant
volume separately to examine the efficacy of treatment
on each population.
In order to best measure the efficacy of radiation treatment, we decided to quantify two basic features of each
simulation as a metric to determine the magnitude of influence each of our dosage strategies had on the growth of
the simulated tumor population. Those are tumor volume
and the tumor volume integrated in time, or area under
the curve. While tumor volume is the most obvious metric to follow in order to measure the efficacy of simulated
treatment, the area under the curve is also an important
metric to follow because it represents the tumor volume
integrated over the treatment period, which gives you an
idea of the overall burden placed on the patient during
that period of time.

3.1

Alvarez, Storey, Kannan, Cho

Comparison of constant dosage
strategies with different dose levels

In this section, we study radiotherapy schedules in which
the dosage value and time interval remain constant over
the six-week treatment period. In particular, we compare different dosage levels, from 1 Gy to 4 Gy, while
increasing the time interval between each administered
dose for stronger dosages to keep the total dose at the
end of 6 weeks constant, at 42 Gy in total. The case of
www.sporajournal.org

Figure 1: Examples of radiotherapy dosage schedules
tested in this study. The clinical standard dosage plan
for prostate cancer is 2 Gy on weekdays, Monday to Friday, for 6 weeks (top). The middle figures show examples of constant dosage schedules studied in section 3.1,
e.g., 1 Gy every day plan (middle, left) and 3 Gy every
3 days plan (middle, right). The bottom figures show
the dosage schedules tested in section 3.2, e.g., Control
schedules using constant dosage (bottom, left) and Experimental schedules using stronger dosage on Friday (bottom, right).
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Figure 2: Comparison of 1 Gy administered every 1 day
(top) versus 2 Gy administered every 2 days (bottom)
to a tumor model initiated as a 1:1 mixture of parental
and resistant tumor cell populations. The results show
the volumes for the individual parental (blue) and resistant (green) populations from the PC3 cell line (left) and
DU145 cell line (right). When subjected to this change,
a 30% decrease in average tumor volume can be seen in
the PC3 cell line when comparing the 1 Gy schedule and
2 Gy schedule. This change in average tumor size is not
as noticeable in the DU145 cell line, as average tumor
size remains unaffected, but a larger variation of values
is noticed. See Tables 3–4 and Figure 3 for further comparison.

Figure 3: A line graph representing total final tumor volume for the PC3 cell line (left) based on values from Table 3 as well as the DU145 cell line (right) based on values
in Table 4. Increasing both dosage values and the time
intervals in between dosages will not change the overall
dosage, so results are dependent on hypofractionation and
not an increased overall dosage. This strategy provides
promising results for the PC3 cell line, but not so much
for the DU145 cell line.

Alvarez, Storey, Kannan, Cho

4 Gy has a lower total dosage due to the 6 week time
constraint, but still continues the observed trend even at
40 Gy total. This strategy is called hypofractionation.
In Tables 3 and 4, we can compare the results generated by ramping up dosage values as well as increasing
the time in between each administered dose. By organizing these events according to their respective dosage and
time interval increase, we can show a clear trend in the
data for the PC3 cell line, as shown in Table 3, in which
a higher dose administered over a greater period of time
gives better results than a lower dose administered over a
shorter length of time. For example, 2 Gy administered
every 2 days yields better results than 1 Gy administered
every 1 day. As an example, in Figure 2, we show the tumor trajectory for the case of comparing a single (1 Gy)
dose administered every 1 day versus a 2 Gy dose administered every 2 days in both cell lines. Figure 2 follows
the basic parameters listed in Table 2. It is important to
note that the PC3 and DU145 cell lines are defined by
their own separate parameters and therefore present with
varying changes after dosage administration. For example, the resistant population of tumor cells in the PC3
cell line have a higher carrying capacity, growth rate, and
higher levels of radio-sensitivity than do resistant cells in
the DU145 cell line. The same is true for parental cells in
the DU145 cell line vs. parental cells in the PC3 cell line.
This is why, despite it being seemingly counterintuitive,
we see resistant cells end with a smaller volume than the
more radiation-sensitive parental cells in the DU145 cell
line. In this instance, one should consider the growth rate
of the parental population and how it far exceeds that of
the resistant cells.
In Figure 2 we can see significant decay for the PC3
cell line in both final tumor size and the area under the
curve. In particular, the average tumor volume shows
a 30% decrease when comparing the 1 Gy schedule and
2 Gy schedule. However, results did not prove to be as
effective for the DU145 cell line, as shown in Table 4 and
Figure 3, since only a slight decrease in the area under
the curve is observable, and hardly any change can be
noted from the final volume of the tumor. In particular,
the parental DU145 cell line shows increasing final tumor
volume as dosages become stronger. Therefore, out of the
two cell lines, it would be safe to assume that this dosage
strategy proves effective only for the PC3 cell line and
not the DU145 cell line. We will further investigate the
underlying mechanism that makes the contrast between
the two cell lines in the future.

3.2

Comparison of uniform dosage
versus stronger dosage on Fridays

Next, we study various scenarios in which no radiation
would be administered over the weekend, to more closely
www.sporajournal.org
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Table 3: PC3 Cell line: Final tumor volume after treatment and area under the curve following an increase in time
interval with stronger dosage, while maintaining a constant overall dosage (i.e., under different hypofractionation
strategies). A steep decrease in final tumor volume was observed, as well as a decrease in the area under the curve.

Final Tumor Volume

Area Under Curve

Dosage (Gy)
Time Interval (days)
Parental
Resistant
Total
Parental
Resistant
Total

1
1
0.0020287
0.66080
0.662823
298.16
1046.4
1344.5

2
2
0.00043197
0.56423
0.56466
277.67
911.99
1189.7

3
3
0.000076458
0.41890
0.41808
262.53
791.61
1054.1

4
4
0.0000069054
0.22569
0.22570
251.33
694.12
945.45

Table 4: DU145 Cell line: Final tumor volume after treatment and area under the curve following an increase in time
interval with stronger dosage, while maintaining a constant overall dosage (i.e., under different hypofractionation
strategies). While a decrease in the area under the curve can be noted, the final tumor volumes of parental and
resistant populations yielded results with no obvious downward trend.

Final Tumor Volume

Area Under Curve

Dosage (Gy)
Time interval (days)
Parental
Resistant
Total
Parental
Resistant
Total

resemble a real-life scenario in which the radiotherapy
clinic would be closed on the weekends, therefore unable
to administer any radiation to a patient during this time
frame. This weekend time frame allows for unchecked
tumor growth for approximately 3 days until the next
dose of radiation is administered. The standard radiation dosage strategy for most radiotherapy clinics would
be a consistent administration of 2 Gy of radiation every weekday, and 0 Gy on weekends. However, instead
of administering a constant radiation dose of 2 Gy every
weekday, we decided to allocate more radiation at the
end of the week (on Friday) at the expense of lowering
the radiation dose for all of the days prior. The idea is to
maintain the same total amount of radiation at the end
of each week so as to not compromise the total amount of
radiation the patient receives, however instead of maintaining a consistent dosage throughout, we can modify
the administration of radiation so that more of it is administered at the end of each week in order to combat
weekend tumor growth.
We considered two different scenarios (Scenario A and
Scenario B) to test how a simulated tumor model might
shift as we vary the dosage values and their respective
time intervals. We also provide a variation on either
scenario (Scenario A′ and Scenario B′ ) in order to conwww.sporajournal.org

1
1
0.5162
0.34821
0.86444
836.98
661.44
1498.4

2
2
0.53188
0.34030
0.87218
794.75
624.52
1419.3

3
3
0.53996
0.32530
0.86526
757.06
590.47
1347.5

4
4
0.526363
0.29257
0.81893
742.58
569.93
1312.5

firm the consistency of a stronger Friday dose by changing the Friday dosage value. We compared the results
from dosing every weekday (Scenarios A and A′ ) versus
dosing every Monday, Wednesday, and Friday (Scenarios
B and B′ ). However, we integrated the aforementioned
guiding principle in this investigation, i.e. stronger doses
given at the end of each week on Fridays, to compensate
for the weekend time intervals spent without radiotherapy. For example, in this investigation, we administered
a higher dosage on Fridays than on any other weekday,
and then we allowed the tumor to “re-grow” on the weekends to represent a lack of radiotherapy treatment given
within that time frame. We used “end-of-week” values as
our main metric for determining the effectiveness of each
treatment modification, and each of these values are measured every Friday after radiation administration. Each
scenario is as follows. We remark that the dosage schedule of scenarios A and B are plotted as bar graph in the
bottom of Figure 1.
• Scenario A involved the simulated administration of
1.8 Gy every day for five days to total 9 Gy at the
end of every week as our control group. In our experimental group this weekly 9 Gy value was maintained while varying daily dosage values. The dosage
2022 Volume 8(1) page 21
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value in our experimental group would increase from
Wednesday, and 3.5 Gy on Friday. This totals 7.5 Gy
1.75 Gy every day Monday–Thursday, to a slightly
at the end of the week each week. Similar results to
higher dose of 2 Gy every Friday. This sums to 9 Gy
Scenario B were observed, with a steady decrease in
at the end of every week, same as the control group.
end-of-week tumor volume values. See tables A7 and
Figures 5 and 6 depict the results of these changes in
A8 in the Appendix for numerical results as well as
either of the PC3 or DU145 cell lines, which shows
Figure A2 for a graphical representation.
only a slight decrease in total tumor volume for the
Scenarios A and A′ show us that by concentrating a
experimental group as a result of these changes. Tables A1 and A2 in the Appendix list parental and re- higher dosage at the end of the week while maintaining
sistant end-of-week tumor volume sizes for the PC3 a consistent weekly dosage, we end up with a smaller tumor volume at the end of each week for both cell lines.
and DU145 cell lines in Scenario A, respectively.
Scenarios B and B′ combined this idea with the previ• Scenario A′ involved a similar process, administerously discussed idea of allowing for more time in between
ing 2 Gy every day for five days as our control, and
larger doses. We reconfirm the effectiveness of concen1.75 Gy Monday–Thursday and 3 Gy on Friday as
trating a higher dosage on Friday compared to Monday
our experimental schedule. We remark that the conand Wednesday in these scenarios. Smaller final tumor
trol case is one of the standard clinical treatment
volumes are obtained in both cell lines. However, when
schedules. This totals 10 Gy at the end of every
we compare scenario A versus B, that is, smaller dosages
week. Similar results to Scenario A were observed,
every five days versus larger dosages on every other day,
with a steady decrease in end-of-week tumor volume
scenario B is more effective than scenario A only in the
values. This change resulted in a much larger differPC3 cell line, not in the DU145 cell line. This is consistent
ence between experimental and control values than
with the results obtained in section 3.1, hypofractionation
Scenario A, however, and A′ more clearly exhibits
is effective only in PC3 cell line, but not in DU145 cell
the benefits of a stronger Friday dosage. See tables
line, even when combined with the stronger dosage on FriA5 and A6 in the Appendix for numerical results as
day strategy. We remark that increasing the total dosage
well as Figure A1 for a graphical representation.
using the same strategy always results in smaller tumor
Scenarios B and B′ consist of a variation from scenarios size. For instance, A′ with total dosage 10 Gy is more
A and A′ , in which a dose is administered every Monday, effective than A with total dosage 9 Gy and B with total
Wednesday and Friday (skipping Tuesday and Thursday), dosage 9 Gy is more effective than B′ with total dosage
still incorporating a stronger Friday dosage. The motiva- 7.5 Gy.
tions behind this were to incorporate some of the findings
from earlier on in the paper to this dosage strategy as well,
Conclusion and Future Outlook
that being the effectiveness of increasing the time inter- 4
val in between doses while maintaining a constant overall
In this study, we sought to study the effect of different
dosage.
radiation dosing strategies on the growth of prostate tu• Scenario B involved administering 3 Gy every Mon- mor spheroids consisting of a heterogeneous mixture of
day, Wednesday and Friday for our control. Our ex- parental and radiation-resistant populations. Our results
perimental regime included 2.5 Gy on Monday and show that the administration of a higher dose with a
Wednesday, and 4 Gy on Friday. This totals 9 Gy at longer period of time in between doses gives more promisthe end of each week. These values show a promis- ing results for the PC3 cell line, but not necessarily for
ing decrease in end-of-week tumor volume size when the DU145 cell line. However, shifting dosage values so
concentrating a greater dose on Fridays. Figure 4 de- that more of it is administered on Friday and less durpicts the first two weeks of this scenario in both the ing the week yields a moderate decrease in tumor volume
control and experimental groups for either cell line at the end of each week for both cell lines. Our results
as a side-by-side comparison. Figures 5 and 6 show showed us that by simply shifting dosage administration
the difference between control and experimental tu- values so that more of it is administered on Fridays, this
mor volumes as a result of these changes in dosage will yield lower overall tumor volume outcomes the more
for the PC3 and DU145 cell lines, respectively. See you shift the dosage values, as seen in both cell lines in
tables A3 and A4 in the Appendix for end-of-week Scenarios A and B. Combining this shift in dosage valvalues.
ues with hypofractionation strategies yields much more
• Similarly to Scenario B, Scenario B′ involved ad- promising results in PC3 cell line, as noted in Scenarministering a certain dosage, 2.5 Gy, every Monday, ios B and B′ . It is important to note that all tests were
Wednesday and Friday for our control. Our exper- run in a simulated 1:1 ratio environment, and it would
imental schedule consists of 2 Gy on Monday and be insightful to look into other heterogeneous mixtures of
www.sporajournal.org

2022 Volume 8(1) page 22

Effective Dose Fractionation of Radiotherapy

Figure 4: Scenario B - A comparison of 3 Gy administered
every Monday, Wednesday, and Friday (Control, top) vs.
2.5 Gy given on Monday and Wednesday, and 4 Gy every
Friday (Experimental, bottom), in a tumor initiated as a
1:1 mixture of parental (blue) and resistant green tumor
cell populations. The results show the volumes for the individual parental and resistant populations from the PC3
cell line (left) and DU145 cell line (right). Only the first
2 weeks are depicted to show more detail. A modest decrease in values at the end of each week can be noted
for both cell lines. A consistent dose will allow for more
growth on the weekend, however a stronger Friday dose
will yield a larger dip in the graph, increasing overall dosing effectiveness.

www.sporajournal.org
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parental and radiation resistant tumor populations. It is
also important to note that the significant difference in
results from the PC3 and DU145 cell lines shows us the
impact of the diversity of the tumor population itself on
radiation treatment.
We conclude from our results that we can improve the
treatment for a 1:1 PC3 cell line mixture using a combination of both methods tested. Many different types
of treatments are possible in this manner, but one such
strategy is proposed in Figure 7. In this scheme, 3 Gy
of radiation is administered daily for the first week, with
a 4 Gy dose administered on the first Friday. Afterward
a constant dose of 2 Gy is administered every Monday,
Wednesday, and Friday for 5 weeks, with a final dose of
3 Gy administered at the end of the 6-week time period.
No radiation is administered on any weekend. This sample combination strategy assimilates both ideas described
in this paper; such that when the tumor is at its largest
we may give a stronger overall dose at the first week with
a stronger dose on the first Friday, and then afterward apply hypofractionation strategies from weeks 2–6. Because
a standard clinical radiotherapy procedure would involve
applying 10 Gy per week, and in this scenario the tumor
undergoes standard radiotherapy procedures for a 6-week
time frame, then this proposal strategy follows that 60 Gy
limit while providing a higher dose of radiation at the
first week. While this greatly slows future growth from
weeks 2–6 in the model (along with the effectively proven
implemented hypofractionation strategies), the effects of
increasing the radiation dosage in the first week by about
60% at the outset may have adverse biological effects that
would need to be observed in a laboratory setting.
In essence, this proposal offers a starting point to what
may be a simulation-based approach to radiotherapy that
would need to be balanced with the biological limitations
of living cells. A more balanced approach would only be
possible after testing various simulation-based radiotherapy dosage strategies in a laboratory setting, and then
possibly using a feedback approach to integrate the results of each tested strategy into a simulation that can
better optimize each strategy with the use of more data.
When it comes to a 1:1 PC3 cell line mixture, comparison of this dosage strategy to our previous findings
shows us that implementation of both the usage of constant dosage strategies with adaptive dose levels, as well
as a stronger dose on Fridays, proves to be more effective than using just one of the two strategies by itself.
Table 5 compares values between our proposed dosage
strategy and results from Table 3, and Table 6 compares
values between Scenario A, defined in Table A5, and our
proposed dosage plan. Both data sets show a clear drop
in tumor volumes, proving the effectiveness of combining
both strategies together.
Clinicians may be able to propose varying dosage
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Figure 5: PC3 cell line for Scenario A (top) and Scenario B (bottom). Each bar represents the total tumor volume
at the end of each week for either the control population (blue) or the experimental population (orange). 9 Gy are
administered every week for a period of 6 weeks for either scenario. Scenario A presents a slight decrease between
experimental and control populations, but by combining the two strategies, Scenario B presents itself as a much more
promising approach in decreasing overall tumor volume at the end of each week and across all 6 weeks of treatment.

Figure 6: DU145 cell line for Scenario A (top) and Scenario B (bottom). Each bar represents total tumor volume at
the end of each week. Control - blue, experimental - orange. 9 Gy are administered in a single week. DU145 presents
with similar results as the PC3 cell line when following the same dosage protocol described in Scenario A, however
as per the previous section, implementing increasing time intervals in between tumor fractionation is not as effective
for the DU145 cell line as it is for the PC3 cell line, therefore it presents with worse overall results than Scenario A
for DU145, confirming the ineffectiveness of hypofractionation on DU145.

Figure 7: Proposed dosage strategy (top) applied to a tumor initiated as a 1:1 mixture of parental and resistant PC3
cell line (bottom). In the first week, 3 Gy administered daily, with 4 Gy administered on the first Friday. Afterward
a constant dose of 2 Gy is administered every Monday, Wednesday, and Friday for 5 weeks, with a final dose of 3 Gy
administered at the end of the 6 week time period. The results show the volumes for the individual parental and
resistant populations. As detailed in Tables 5 and 6, our proposed dosage strategy results in the smallest final tumor
volume compared to all dosage plans tested in the previous sections and the standard clinical schedule.
www.sporajournal.org
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Table 5: Comparison of values between data collected from our simulation of the standard clinical radiotherapy
schedule (a constant 2 Gy dose every weekday with a break on weekends) and results from our proposed dosage
strategy. Both models used PC3 cell line parameters. A clear decrease in final tumor volume and total area can be
observed in both parental and resistant populations after implementation of the proposed dosage strategy.

Final Tumor Volume

Area Under Curve

Parental
Resistant
Total
Parental
Resistant
Total

Standard Clinical
Radiotherapy Schedule
1.0739 × 10−7
0.030486
0.030486
19.910
140.41
160.32

Proposed
Dosage Strategy
1.0790 × 10−8
0.0074191
0.0074191
6.1733
33.693
39.866

Table 6: Comparison of values between the standard clinical radiotherapy model,) results referenced in Table A5,
and our proposed dosage strategy. Scenario A involved administering 1.75 Gy every day from Monday through
Thursday and then 3 Gy every Friday, as well as withholding any radiation on weekends. We mirrored this scheme
more effectively in our proposed strategy, as exhibited by the decrease in end-of-week values for all six weeks. Our
proposed strategy proved to be most effective.
Tumor Volume

week 1

week 2

week 3

week 4

week 5

week 6
−5

6.8229 × 10−6
0.0073082
0.0073150

Parental
Clinical
Resistant
Standard
Total

0.051106
0.15534
0.20645

0.0077640
0.064823
0.072587

0.0013167
0.034116
0.035433

0.00022713
0.019652
0.019879

3.9305 × 10
0.011837
0.011876

Parental
Scenario A Resistant
Total

0.044009
0.13129
0.17530

0.0063787
0.052691
0.059070

0.0010296
0.026704
0.027734

0.00016888
0.014785
0.014954

2.7777 × 10−5 4.5829 × 10−6
0.0085415
0.0050479
0.0085693
0.0050525

Parental
Proposed
Resistant
Strategy
Total

0.00039753 3.4299 × 10−5 2.9631 × 10−6 2.5612 × 10−7 2.2186 × 10−8 3.6478 × 10−9
0.0097035
0.0061374
0.0039301
0.0025354
0.0016432
0.0017628
0.010101
0.0061717
0.0039331
0.0025357
0.0016432
0.0017628

strategies prior to the treatment cycle depending on the
cell mixture, cell line, size, and growth rate of the tumor
in order to fit the needs of each individual patient. This
proposal would be most effective in theory on this particular cell line (PC3) within a 1:1 mixture of parental
to radio-resistant cells. Due to the particularity of each
tumor in any individual patient, the importance of math
modeling in clinical radiotherapy remains well-grounded,
as ODE models can be used to predict the most effective course of treatment in any particular case, as opposed to following standard procedure that does not take
into account all of the variables involved in each individual tumor population, such as tumor heterogeneity. Our
hope is that in the future, with the help of ever-advancing
medical technology, patients’ tumors may be able to be
paramaterized in a similar manner to this study, and then
those parameters can be modeled using ODE’s that can
extrapolate the approximate growth behavior of the tumor. Using this extrapolation, the best possible dosage
strategy can be approximated using much more advanced
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optimization strategies than those implemented here, but
also one that builds upon the framework proposed earlier
in this paper.
Of note to point out is that all experiments in this simulation study were done in silico, and although parameters were derived from experiments, the natural world
contains many other complex parameters that cannot yet
be replicated within a computer simulation. Therefore,
further means of study and real-life investigations are necessary before we can apply the findings of this study to a
clinical application. In addition, side effects and toxicity
of using higher dosage has to be addressed [1, 34]. That
being said, our work underscores the potential of adaptive cancer treatments, which is of recent interest in the
field. In particular, this concept can be applied to those
patients that have heterogeneous mixtures of cancer, with
both temporal and spatial variability in their cancer microenvironment and even therapy-induced perturbations.
In our future work, we propose to do further analysis
into different prostate cancer cell lines, such as the DU145
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cell line to examine the efficacy of adaptive dosages.
While the PC3 cell line showed promising results using
the hypofractionation strategy, the DU145 cell line did
not. This could be due to various factors, including the
differences in the proliferation rate and interaction types
of the populations. We aim to further identify the key
parameters and underlying mechanisms that yield such
differences to identify the cancer types and patients that
hypofractionation strategy should be applied to. Our final goal is to develop strategies for cancer cell lines with
different interaction properties to improve treatment outcome. Comparing other radiotherapy models with our
current choice, the linear-quadratic model with instant
response, will be our future work as well. It will be interesting to validate our results across different radiotherapy
models including a logistic type of radiotherapy model
[27, 25], dynamic carrying capacity [36], and delayed response from necrotic population [7]. In the future, we also
hope to do prospective experiments to examine the efficacy of proposed dosage strategies, in addition to studying other initial mixture ratios.
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Figure A1: End-of-week tumor volumes in graphical format for Scenario A′ on the PC3 cell line (top) and on the
DU145 cell line (bottom). Scenario A′ shows the effectiveness of a higher Friday dosage without the implementation
of hypofractionation strategies on either cell line (as in Scenarios B and B′ ). While weekly dosage is higher than
that of Scenarios A and B (10 Gy vs 9 Gy), this value is consistent between control and experimental simulations
within this scenario, meaning the difference in end-of-week tumor volumes seen between the control and experimental
simulations is entirely due to a stronger Friday dosage.

Figure A2: End-of-week tumor volumes in graphical format for Scenario B′ on the PC3 cell line (top) and on the
DU145 cell line (bottom). This scenario involves administration of only 7.5 Gy every week, and implements a stronger
Friday dosage as well as hypofractionation strategies discussed earlier. While a stronger Friday dosage is still effective
for either cell line, hypofractionation strategies remain minimally effective to the overall tumor volume of DU145 cell
line.
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Table A1: PC3 cell line for Scenario A. Values represent tumor volume at the end of each week. Control: 1.8 Gy
administered Monday through Friday; Experimental: 1.75 Gy administered Monday through Thursday, 2 Gy administered on Friday. 9 Gy administered in a single week.
Tumor Volume

week 1

week 2

week 3

week 4

week 5

week 6

Control

Parental
Resistant
Total

0.084901
0.22261
0.30751

0.021027
0.12080
0.14183

0.0061529
0.083701
0.089854

0.0018777
0.064383
0.066261

0.00058006
0.052479
0.053059

0.00017988
0.044384
0.044564

Experimental

Parental
Resistant
Total

0.082921
0.21667
0.29959

0.020487
0.11725
0.13774

0.0059828
0.081114
0.087097

0.0018221
0.062311
0.064133

0.00056178
0.050729
0.051291

0.00017386
0.042854
0.043028

Table A2: DU145 cell line for Scenario A. Values represent tumor volume at the end of each week. Control:
1.8 Gy administered Monday through Friday; Experimental: 1.75 Gy administered Monday through Thursday, 2 Gy
administered on Friday. 9 Gy administered in a single week.
Tumor Volume

week 1

week 2

week 3

week 4

week 5

week 6

Control

Parental
Resistant
Total

0.15188
0.23423
0.38611

0.066600
0.13887
0.20547

0.036114
0.10169
0.13780

0.021379
0.081892
0.10327

0.013240
0.069616
0.082856

0.0084134
0.061283
0.069696

Experimental

Parental
Resistant
Total

0.14927
0.23038
0.37965

0.065328
0.13631
0.201638

0.035387
0.099727
0.13511

0.020933
0.080260
0.10119

0.012954
0.068197
0.081151

0.0082259
0.060011
0.068237

Table A3: PC3 cell line for Scenario B. Values represent tumor volume at the end of each week. Control: 3 Gy
administered Monday, Wednesday, and Friday; Experimental: 2.5 Gy administered Monday and Wednesday, 4 Gy
on Friday. 9 Gy administered in a single week.
Tumor Volume

week 1

week 2

week 3

week 4

week 5
−5

Control

Parental
Resistant
Total

0.019411
0.15839
0.17780

0.0015771
0.066878
0.068455

0.00013555
0.035654
0.035790

1.1705 × 10
0.020827
0.020839

Experimental

Parental
Resistant
Total

0.016345
0.12392
0.14027

0.0012511
0.049846
0.051097

0.00010121
0.025389
0.025490

8.2218 × 10−6
0.014144
0.014152

week 6
−6

8.7391 × 10−8
0.0079866
0.0079867

6.6823 × 10−7
0.0082270
0.0082277

5.4331 × 10−8
0.0048978
0.0048979

1.0112 × 10
0.012734
0.012735

Table A4: DU145 cell line for Scenario B. Values represent tumor volume at the end of each week. Control: 3 Gy
administered Monday, Wednesday, and Friday; Experimental: 2.5 Gy administered Monday and Wednesday, 4 Gy
on Friday. 9 Gy administered in a single week.
Tumor Volume

week 1

week 2

week 3

week 4

week 5

week 6

Control

Parental
Resistant
Total

0.22442
0.20989
0.43431

0.15275
0.11644
0.26919

0.12874
0.080110
0.20881

0.11798
0.060718
0.17870

0.11256
0.048637
0.16120

0.10967
0.040383
0.15005

Experimental

Parental
Resistant
Total

0.18009
0.18451
0.36460

0.12056
0.10023
0.22079

0.10093
0.068033
0.16896

0.092219
0.050978
0.14320

0.087874
0.040404
0.12828

0.085586
0.033206
0.11879
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Table A5: PC3 cell line for Scenario A′ . Control: 2 Gy administered Monday through Friday; Experimental: 1.75 Gy
administered Monday through Thursday, 3 Gy administered on Friday. 10 Gy administered in a single week.
Tumor Volume
Control

Experimental

week 1

week 2

week 3

week 4

week 5

week 6

Parental
Resistant
Total

0.051106
0.15534
0.20645

0.0077640
0.064823
0.072587

0.0013167
0.034116
0.035433

0.00022712
0.019652
0.019879

0.000039305
0.011837
0.011876

0.0000068229
0.0073082
0.0073150

Parental
Resistant
Total

0.044009
0.13129
0.17530

0.0063787
0.052691
0.059070

0.0010296
0.026704
0.027734

0.00016888
0.014785
0.014954

0.000027777
0.0085415
0.0085693

0.0000045829
0.0050479
0.0050525

Table A6: DU145 cell line for Scenario A′ . Control: 2 Gy administered Monday through Friday; Experimental:
1.75 Gy administered Monday through Thursday, 3 Gy administered on Friday. 10 Gy administered in a single week.
Tumor Volume
Control

Experimental

week 1

week 2

week 3

week 4

week 5

week 6

Parental
Resistant
Total

0.11442
0.18871
0.30313

0.040030
0.096959
0.13699

0.017021
0.061894
0.078915

0.0077624
0.043493
0.051255

0.0036484
0.032255
0.035903

0.0017389
0.024753
0.026492

Parental
Resistant
Total

0.10364
0.17204
0.27568

0.035558
0.086988
0.12255

0.014866
0.054900
0.069766

0.0066652
0.038185
0.044850

0.0030785
0.028037
0.031116

0.0014413
0.021301
0.022742

Table A7: PC3 cell line for Scenario B′ . Values represent tumor volume at the end of each week. Control: 2.5 Gy
administered Monday, Wednesday, and Friday; Experimental: 2 Gy administered Monday and Wednesday, 3.5 Gy
on Friday. 7.5 Gy administered in a single week.
Tumor Volume
Control

Experimental

week 1

week 2

week 3

week 4

week 5

week 6

Parental
Resistant
Total

0.046328
0.28760
0.33393

0.0090815
0.18373
0.19281

0.0020226
0.14793
0.14995

0.00046238
0.13083
0.13129

0.00010633
0.12139
0.12150

0.000024483
0.11577
0.11579

Parental
Resistant
Total

0.037598
0.21896
0.25656

0.0069530
0.13435
0.14130

0.0014604
0.10526
0.10672

0.00031438
0.091107
0.091421

0.000068035
0.083055
0.083123

0.000014740
0.078059
0.078074

Table A8: DU145 cell line for Scenario B′ . Values represent tumor volume at the end of each week. Control: 2.5 Gy
administered Monday, Wednesday, and Friday; Experimental: 2 Gy administered Monday and Wednesday, 3.5 Gy
on Friday. 7.5 Gy administered in a single week.
Tumor Volume
Control

Experimental

www.sporajournal.org

week 1

week 2

week 3

week 4

week 5

week 6

Parental
Resistant
Total

0.32275
0.29400
0.61675

0.24864
0.20008
0.44872

0.22279
0.16489
0.38768

0.21006
0.14745
0.35751

0.20257
0.13762
0.34019

0.19766
0.13169
0.32935

Parental
Resistant
Total

0.25674
0.25608
0.51282

0.19434
0.17060
0.36494

0.17308
0.13906
0.31214

0.16272
0.12344
0.28616

0.15668
0.11460
0.27128

0.15274
0.10922
0.26196
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